Wynzora

Wynzora combines betamethasone and calcipotriol for topical treatment of plaque psoriasis. This corticosteroid and vitamin D analogue reduces inflammation and skin cell overgrowth. Suitable for adults seeking localized relief from psoriatic lesions.

Wynzora is used to treat mild to moderate plaque psoriasis in adults. It helps reduce redness, scaling, and thickness of psoriatic plaques. The medication works by slowing skin cell production and calming immune responses in affected areas. Wynzora is applied directly to the skin for targeted relief.

Wynzora typically reduces visible signs of psoriasis within weeks of consistent use. Users may notice decreased redness and smoother skin texture in treated areas. Some individuals experience mild skin dryness or irritation at the application site. Results vary based on skin type and severity of symptoms.

Avoid applying Wynzora to broken or infected skin. Do not use on the face, groin, or underarms unless directed by a healthcare provider. Keep the medication away from eyes and mucous membranes. Wash hands thoroughly after application to prevent accidental transfer.

Wynzora may interact with other topical medications applied to the same area. Avoid combining with strong corticosteroids or high-potency vitamin D analogues. Inform your doctor about all products used on your skin to prevent potential reactions. Alcohol-based products may increase skin dryness.